Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.0K
Clinical Trials01:16

Clinical Trials

9.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.4K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

39
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
39
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

932
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
932
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

49
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
49

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ivonescimab: The Next United States Food and Drug Administration Project Optimus Flashpoint?

JTO clinical and research reports·2026
Same author

Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation.

Clinical and translational science·2026
Same author

<i>TPMT</i>-Cisplatin: Lessons in Citation Integrity and Scientific Oversight.

JCO oncology practice·2026
Same author

Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Potential alternative dosage strategies for patent-protected oral cancer drugs.

European journal of cancer (Oxford, England : 1990)·2025

Related Experiment Video

Updated: Nov 5, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K

The Right Dose: From Phase I to Clinical Practice.

Stefanie L Groenland1, Mark J Ratain2, Lisa S Chen3

  • 1Department of Clinical Pharmacology, Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, Netherlands.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 19, 2021
PubMed
Summary

Optimizing anticancer drug dosing, especially for oral targeted therapies, is crucial. Strategies like therapeutic drug monitoring and dose adjustments can reduce toxicity and improve patient outcomes.

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

Related Experiment Videos

Last Updated: Nov 5, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.9K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Optimizing anticancer drug dosage is essential for maximizing therapeutic potential.
  • Oral targeted therapies present unique dosing challenges due to high interindividual variability.

Purpose of the Study:

  • To explore strategies for optimizing anticancer drug dosing, with a focus on oral targeted therapies.
  • To highlight the importance of individualized dosing for improved patient outcomes and reduced toxicity.

Main Methods:

  • Discusses therapeutic drug monitoring (TDM) for optimizing drug exposure.
  • Explores dose adjustments, including more frequent smaller doses and administration under specific prandial conditions.
  • Reviews the potential for lower, off-label doses to mitigate toxicity.

Main Results:

  • Therapeutic drug monitoring may optimize exposure if the target concentration is known, particularly for oral kinase inhibitors.
  • Current labeled doses may lead to excessive toxicity in many patients.
  • Lower off-label doses show potential in reducing both medical and financial toxicity.

Conclusions:

  • Individualized dosing strategies, including TDM and dose adjustments, are vital for optimizing anticancer treatment.
  • Applying these strategies from drug registration to clinical practice can enhance patient care.
  • Reducing excessive dosing can significantly improve the benefit-risk profile of anticancer therapies.